Latest Prednisone Stories

CHICAGO, June 2, 2012 /PRNewswire/ -- Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA(®)) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus...

Phase 3 Results Show Significant Improvement in Radiographic Progression-Free Survival and a Trend for Increased Overall Survival in Patients Receiving ZYTIGA® Plus Prednisone TORONTO, June 2, 2012 /CNW/ - New data presented this weekend at the 48(th) annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA® (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy....

DEERFIELD, Ill., May 29, 2012 /PRNewswire/ -- Horizon Pharma, Inc. (NASDAQ: HZNP) announced today that the U.S. Patent and Trademark Office has issued patent number 8,168,218 titled "Delayed Release Tablet with Defined Core Geometry" that covers RAYOS® (5 mg Delayed-Release Prednisone). Horizon is the licensee of the SkyePharma group of companies in respect of the patent and SkyePharma's related proprietary Geoclock(TM) technology. "This patent issuance for RAYOS is another...

RARITAN, N.J., May 18, 2012 /PRNewswire/ -- Data related to ZYTIGA® (abiraterone acetate) clinical studies have been selected for presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO). Additionally, data regarding the investigational compounds ibrutinib and siltuximab also have been accepted for presentation. Additional abstracts were also accepted as publication-only or in the trial in progress category. These studies were sponsored by...

A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate, according to a clinical study to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO), June 1-5, in Chicago. The phase II clinical trial, led by investigators at Dana-Farber Cancer Institute and other research centers, examined the use...

Muscular Dystrophy Association has awarded ReveraGen BioPharma $1.5 million to develop drug TUCSON, Ariz., May 3, 2012 /PRNewswire-USNewswire/ -- The Muscular Dystrophy Association announced today that it has awarded $1,549,725 to ReveraGen BioPharma, a Rockville, Md., biotechnology company, to develop and test a "dissociative glucocorticoid" as a potential treatment for Duchenne muscular dystrophy (DMD). (Logo: http://photos.prnewswire.com/prnh/20120424/DC93207LOGO) MDA has...

RARITAN, N.J., March 8, 2012 /PRNewswire/ -- Janssen Research & Development, LLC today announced that it has unblinded the Phase 3 study of ZYTIGA® (abiraterone acetate) plus prednisone for the treatment of asymptomatic or mildly symptomatic patients with metastatic castration-resistant prostate cancer (CRPC) who have not received chemotherapy. Study COU-AA-302 is an international, randomized, double-blind, placebo controlled study that included 1,088 patients who were...

BOTHELL, Wash. and VANCOUVER, British Columbia, Feb. 2, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today preliminary results from a Phase 2 prostate cancer study with its investigational compound OGX-427, which is designed to inhibit the production of Hsp27. Hsp27 is a cell-survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Overexpression of Hsp27 is thought to be an important...

Stopping immunosuppressive prednisone soon after transplantation found safe Highlights:     Patients who quickly stop taking the immunosuppressant prednisone after receiving a kidney transplant avoid experiencing serious prednisone-related side effects.     This rapid discontinuation of prednisone does not jeopardize the long-term survival of patients and their new organs.     Approximately 16,500 patients receive kidney transplants each year in the United States and must...

TARRYTOWN, N.Y., July 7, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP(TM) (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data...